Table Info

Table 1.

The direct effects of anti-CD99 mAbs in T-ALL

Antibody name	Isotype	Epitope	Effect on T-ALL	Effect on normal cells
DN16	mIgG1	LPDNENKK	Induces apoptosis	Not performed
0662	mIgG3	GSFSDADLA	Induces apoptosis	Not performed
12E7	mIgG1	DGEN	No apoptosis	Not performed
D44	mIgM	Not reported	No apoptosis	Not performed
Ad20	mIgM	Not reported	Induces apoptosis	No apoptosis
10A1	hIgG1^※	ENDDPRPPNPPKPM	Induces apoptosis	No apoptosis
YG32	mIgG	RPPNPPK	No apoptosis Induces homotypic aggregation	Not performed
MT99/3	mIgG2a	Not reported	No apoptosis Induces homotypic aggregation	Not performed
MT99/1	mIgM	Not reported	Induces homotypic aggregation and apoptosis	Not performed
MT99/2	mIgM	Not reported	No homotypic aggregation and no apoptosis	Not performed

^※ Tetravalent antibody. hIgG1: human IgG1

Declarations

Author contributions

KK: Conceptualization, Writing—original draft, Writing—review & editing. WK: Writing—review & editing. NT: Conceptualization, Writing—original draft, Writing—review & editing, Supervision. All authors have read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This work was financially supported by the Office of the Permanent Secretary, Ministry of Higher Education, Science, Research and Innovation (OPS MHESI), Thailand Science Research and Innovation (TSRI) [RGNS 64—068]; and partially supported by Chiang Mai University to NT; the Faculty of Associated Medical Sciences at Chiang Mai University (2022 budget revenue to NT); and the Distinguished Research Professor Grant of the National Research Council of Thailand [NRCT808/2563]; KK has received the Teaching Assistant and Research Assistant (TA/RA) Scholarship from the Graduate School, Chiang Mai University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27:1. [DOI] [PubMed] [PMC]

Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies (Basel). 2020;9:34. [DOI] [PubMed] [PMC]

Safarzadeh Kozani P, Naseri A, Safarzadeh Kozani P, Khatami S, Sheikhi A. Monoclonal antibodies (mAbs) approved for cancer treatment in the 2020s. Trends Med Sci. 2021;1:e116686. [DOI]

Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012;12:14. [PubMed] [PMC]

Drobna M, Szarzynska-Zawadzka B, Dawidowska M. T-cell acute lymphoblastic leukemia from miRNA perspective: basic concepts, experimental approaches, and potential biomarkers. Blood Rev. 2018;32:457–72. [DOI] [PubMed]

Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541–52. [DOI] [PubMed]

Litzow MR, Ferrando AA. How I treat T-cell acute lymphoblastic leukemia in adults. Blood. 2015;126:833–41. [DOI] [PubMed]

Bayón-Calderón F, Toribio ML, González-García S. Facts and challenges in immunotherapy for T-cell acute lymphoblastic leukemia. Int J Mol Sci. 2020;21:7685. [DOI] [PubMed] [PMC]

Scherer LD, Brenner MK, Mamonkin M. Chimeric antigen receptors for T-cell malignancies. Front Oncol. 2019;9:126. [DOI] [PubMed] [PMC]

10.

Edgar JD. T cell immunodeficiency. J Clin Pathol. 2008;61:988–93. [DOI] [PubMed]

11.

Helena Mangs A, Morris BJ. The human pseudoautosomal region (PAR): origin, function and future. Curr Genomics. 2007;8:129–36. [DOI] [PubMed] [PMC]

12.

Ellis NA, Tippett P, Petty A, Reid M, Weller PA, Ye TZ, et al. PBDX is the XG blood group gene. Nat Genet. 1994;8:285–90. [DOI] [PubMed]

13.

Pasello M, Manara MC, Scotlandi K. CD99 at the crossroads of physiology and pathology. J Cell Commun Signal. 2018;12:55–68. [DOI] [PubMed] [PMC]

14.

Aubrit F, Gelin C, Pham D, Raynal B, Bernard A. The biochemical characterization of E2, a T cell surface molecule involved in rosettes. Eur J Immunol. 1989;19:1431–6. [DOI] [PubMed]

15.

Alberti I, Bernard G, Rouquette-Jazdanian AK, Pelassy C, Pourtein M, Aussel C, et al. CD99 isoforms expression dictates T-cell functional outcomes. FASEB J. 2002;16:1946–8. [DOI] [PubMed]

16.

Hahn JH, Kim MK, Choi EY, Kim SH, Sohn HW, Ham DI, et al. CD99 (MIC2) regulates the LFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion. J Immunol. 1997;159:2250–8. [PubMed]

17.

Scotlandi K, Zuntini M, Manara MC, Sciandra M, Rocchi A, Benini S, et al. CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity. Oncogene. 2007;26:6604–18. [DOI] [PubMed]

18.

Lee MK, Kim HS, Kim SS, Cho MH, Lee IS. Analysis of the dimerization of human CD99 using bimolecular fluorescence complementation technique. J Microbiol Biotechnol. 2008;18:472–6. [PubMed]

19.

Bernard A, Aubrit F, Raynal B, Pham D, Boumsell L. A T cell surface molecule different from CD2 is involved in spontaneous rosette formation with erythrocytes. J Immunol. 1988;140:1802–7. [PubMed]

20.

Gelin C, Aubrit F, Phalipon A, Raynal B, Cole S, Kaczorek M, et al. The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product. EMBO J. 1989;8:3253–9. [DOI] [PubMed] [PMC]

21.

Park CK, Shin YK, Kim TJ, Park SH, Ahn GH. High CD99 expression in memory T and B cells in reactive lymph nodes. J Korean Med Sci. 1999;14:600–6. [DOI] [PubMed] [PMC]

22.

Dworzak MN, Fritsch G, Buchinger P, Fleischer C, Printz D, Zellner A, et al. Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood. Blood. 1994;83:415–25. [PubMed]

23.

Gao Q, Yellapantula V, Fenelus M, Pichardo J, Wang L, Landgren O, et al. Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms. Mod Pathol. 2018;31:881–9. [DOI] [PubMed] [PMC]

24.

Gil M, Pak HK, Lee AN, Park SJ, Lee Y, Roh J, et al. CD99 regulates CXCL12-induced chemotaxis of human plasma cells. Immunol Lett. 2015;168:329–36. [DOI] [PubMed]

25.

Chung SS, Eng WS, Hu W, Khalaj M, Garrett-Bakelman FE, Tavakkoli M, et al. CD99 is a therapeutic target on disease stem cells in myeloid malignancies. Sci Transl Med. 2017;9:eaaj2025. [DOI] [PubMed] [PMC]

26.

Manara MC, Pasello M, Scotlandi K. CD99: a cell surface protein with an oncojanus role in tumors. Genes (Basel). 2018;9:159. [DOI] [PubMed] [PMC]

27.

Kang LC, Dunphy CH. Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes. Arch Pathol Lab Med. 2006;130:153–7. [DOI] [PubMed]

28.

Dworzak MN, Fröschl G, Printz D, Zen LD, Gaipa G, Ratei R, et al. CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease. Leukemia. 2004;18:703–8. [DOI] [PubMed]

29.

Scotlandi K, Perdichizzi S, Bernard G, Nicoletti G, Nanni P, Lollini PL, et al. Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing’s sarcoma. Eur J Cancer. 2006;42:91–6. [DOI] [PubMed]

30.

Takheaw N, Sittithumcharee G, Kariya R, Kasinrerk W, Okada S. Anti-human CD99 antibody exerts potent antitumor effects in mantle cell lymphoma. Cancer Immunol Immunother. 2021;70:1557–67. [DOI] [PubMed]

31.

Ebadi M, Jonart LM, Ostergaard J, Gordon PM. CD99 antibody disrupts T-cell acute lymphoblastic leukemia adhesion to meningeal cells and attenuates chemoresistance. Sci Rep. 2021;11:24374. [DOI] [PubMed] [PMC]

32.

Choi EY, Park WS, Jung KC, Kim SH, Kim YY, Lee WJ, et al. Engagement of CD99 induces up-regulation of TCR and MHC class I and II molecules on the surface of human thymocytes. J Immunol. 1998;161:749–54. [PubMed]

33.

Brémond A, Meynet O, Mahiddine K, Coito S, Tichet M, Scotlandi K, et al. Regulation of HLA class I surface expression requires CD99 and p230/golgin-245 interaction. Blood. 2009;113:347–57. [DOI] [PubMed]

34.

Sohn HW, Shin YK, Lee IS, Bae YM, Suh YH, Kim MK, et al. CD99 regulates the transport of MHC class I molecules from the Golgi complex to the cell surface. J Immunol. 2001;166:787–94. [DOI] [PubMed]

35.

Pata S, Otáhal P, Brdička T, Laopajon W, Mahasongkram K, Kasinrerk W. Association of CD99 short and long forms with MHC class I, MHC class II and tetraspanin CD81 and recruitment into immunological synapses. BMC Res Notes. 2011;4:293. [DOI] [PubMed] [PMC]

36.

Waclavicek M, Majdic O, Stulnig T, Berger M, Sunder-Plassmann R, Zlabinger GJ, et al. CD99 engagement on human peripheral blood T cells results in TCR/CD3-dependent cellular activation and allows for Th1-restricted cytokine production. J Immunol. 1998;161:4671–8. [PubMed]

37.

Yoon SS, Kim HJ, Chung DH, Kim TJ. CD99 costimulation up-regulates T cell receptor-mediated activation of JNK and AP-1. Mol Cells. 2004;18:186–91. [PubMed]

38.

Oh KI, Kim BK, Ban YL, Choi EY, Jung KC, Lee IS, et al. CD99 activates T cells via a costimulatory function that promotes raft association of TCR complex and tyrosine phosphorylation of TCR ζ. Exp Mol Med. 2007;39:176–84. [DOI] [PubMed]

39.

Laopajon W, Pata S, Takheaw N, Surinkaew S, Khummuang S, Kasinrerk W. Triggering of CD99 on monocytes by a specific monoclonal antibody regulates T cell activation. Cell Immunol. 2019;335:51–8. [DOI] [PubMed]

40.

Belver L, Ferrando A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2016;16:494–507. [DOI] [PubMed]

41.

Abromowitch M, Sposto R, Perkins S, Zwick D, Siegel S, Finlay J, et al. Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children’s Oncology Group. Br J Haematol. 2008;143:261–7. [DOI] [PubMed] [PMC]

42.

Weber GF. DNA damaging drugs. In: Molecular therapies of cancer. Springer, Cham; 2014. pp. 9–112.

43.

Amjad MT, Chidharla A, Kasi A. United States: cancer chemotherapy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. [PubMed]

44.

Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030–43. [DOI] [PubMed]

45.

Yu H, Du Y, Xu J, Zhang M. Prognostic relevance of genetic variations in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. Transl Cancer Res. 2019;8:2485–95. [DOI] [PubMed] [PMC]

46.

Leleu X, Martin T, Weisel K, Schjesvold F, Iida S, Malavasi F, et al. Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes. Ann Hematol. 2022;101:2123–37. [DOI] [PubMed] [PMC]

47.

Avivi I, Robinson S, Goldstone A. Clinical use of rituximab in haematological malignancies. Br J Cancer. 2003;89:1389–94. [DOI] [PubMed] [PMC]

48.

Daratumumab for chemotherapy-refractory minimal residual disease in T cell ALL [Internet]. [Cited 2023 Nov 10]. Available from: https://clinicaltrials.gov/study/NCT05289687?cond=T-ALL&term=Antibody&limit=100&page=1&rank=7

49.

Phase II study of KW-0761 in subjects with CCR4-positive adult T-cell leukemia-lymphoma [Internet]. [Cited 2023 Nov 10]. Available from: https://clinicaltrials.gov/study/NCT00920790?cond=T-ALL&term=Antibody&limit=100&page=1&rank=44

50.

Nivolumab in treating patients with HTLV-associated T-cell leukemia/lymphoma [Internet]. [Cited 2023 Nov 10]. Available from: https://clinicaltrials.gov/study/NCT02631746?cond=T-ALL&term=Antibody&limit=100&page=1&rank=48

51.

Caracciolo D, Mancuso A, Polerà N, Froio C, D’Aquino G, Riillo C, et al. The emerging scenario of immunotherapy for T-cell acute lymphoblastic leukemia: advances, challenges and future perspectives. Exp Hematol Oncol. 2023;12:5. [DOI] [PubMed] [PMC]

52.

Jagtap SV. Evaluation of CD4+ T-cells and CD8+ T-cells in triple-negative invasive breast cancer. Indian J Pathol Microbiol. 2018;61:477–8. [PubMed]

53.

Bernard G, Breittmayer JP, de Matteis M, Trampont P, Hofman P, Senik A, et al. Apoptosis of immature thymocytes mediated by E2/CD99. J Immunol. 1997;158:2543–50. [PubMed]

54.

Pettersen RD, Bernard G, Olafsen MK, Pourtein M, Lie SO. CD99 signals caspase-independent T cell death. J Immunol. 2001;166:4931–42. [DOI] [PubMed]

55.

Jung KC, Kim NH, Park WS, Park SH, Bae Y. The CD99 signal enhances Fas-mediated apoptosis in the human leukemic cell line, Jurkat. FEBS Lett. 2003;554:478–84. [DOI] [PubMed]

56.

Gil MC, Lee MH, Seo JI, Choi YL, Kim MK, Jung KC, et al. Characterization and epitope mapping of two monoclonal antibodies against human CD99. Exp Mol Med. 2002;34:411–8. [DOI] [PubMed]

57.

Romero LA, Hattori T, Ali MAE, Ketavarapu G, Koide A, Park CY, et al. High-valency anti-CD99 antibodies toward the treatment of T cell acute lymphoblastic leukemia. J Mol Biol. 2022;434:167402. [DOI] [PubMed] [PMC]

58.

Kasinrerk W, Tokrasinwit N, Moonsom S, Stockinger H. CD99 monoclonal antibody induce homotypic adhesion of Jurkat cells through protein tyrosine kinase and protein kinase C-dependent pathway. Immunol Lett. 2000;71:33–41. [DOI] [PubMed]

59.

Khunkaewla P, Chiampanichayakul S, Yasamut U, Pata S, Kasinrerk W. Production, characterization, and functional analysis of newly established CD99 monoclonal antibodies MT99/1 and MT99/2. Hybridoma (Larchmt). 2007;26:241–50. [DOI] [PubMed]

60.

Weiner LM, Murray JC, Shuptrine CW. Antibody-based immunotherapy of cancer. Cell. 2012;148:1081–4. [DOI] [PubMed] [PMC]

61.

Singh SK, Dorak MT. Cancer immunoprevention and public health. Front Public Health. 2017;5:101. [DOI] [PubMed] [PMC]

62.

Reslan L, Dalle S, Dumontet C. Understanding and circumventing resistance to anticancer monoclonal antibodies. MAbs. 2009;1:222–9. [DOI] [PubMed] [PMC]

63.

Gu T, Zhu M, Huang H, Hu Y. Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches. J Zhejiang Univ Sci B. 2022;23:793–811. [DOI] [PubMed] [PMC]

64.

Shi J, Zhang Z, Cen H, Wu H, Zhang S, Liu J, et al. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity. J Hematol Oncol. 2021;14:162. [DOI] [PubMed] [PMC]

65.

Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. CAR-T cell therapy in T-cell malignancies: is success a low-hanging fruit? Stem Cell Res Ther. 2021;12:527. [DOI] [PubMed] [PMC]

66.

Luo L, Zhou X, Zhou L, Liang Z, Yang J, Tu S, et al. Current state of CAR-T therapy for T-cell malignancies. Ther Adv Hematol. 2022;13:20406207221143025. [DOI] [PubMed] [PMC]